These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18344185)

  • 1. A statistical methodology for drug-drug interaction surveillance.
    Norén GN; Sundberg R; Bate A; Edwards IR
    Stat Med; 2008 Jul; 27(16):3057-70. PubMed ID: 18344185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios.
    van der Heijden PG; van Puijenbroek EP; van Buuren S; van der Hofstede JW
    Stat Med; 2002 Jul; 21(14):2027-44. PubMed ID: 12111885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nurses are increasingly involved in pharmacovigilance in Sweden.
    Ulfvarson J; Mejyr S; Bergman U
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):532-7. PubMed ID: 17072915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events.
    Norén GN; Bate A; Orre R; Edwards IR
    Stat Med; 2006 Nov; 25(21):3740-57. PubMed ID: 16381072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are novel drugs more risky for patients than less novel drugs?
    Olson MK
    J Health Econ; 2004 Nov; 23(6):1135-58. PubMed ID: 15556240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Quality of event data in detection of unwanted drug side-effects in general practice of established physicians].
    Schädlich PK
    Gesundheitswesen; 1993 Feb; 55(1 Suppl):8-12. PubMed ID: 8096773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase.
    Strandell J; Caster O; Bate A; Norén N; Edwards IR
    Drug Saf; 2011 Mar; 34(3):253-66. PubMed ID: 21332249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
    Hauben M; Vegni F; Reich L; Younus M
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system.
    Ortega A; Aguinagalde A; Lacasa C; Aquerreta I; Fernández-Benítez M; Fernández LM
    Ann Pharmacother; 2008 Oct; 42(10):1491-6. PubMed ID: 18780808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
    Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.
    Koh Y; Yap CW; Li SC
    Int J Med Inform; 2008 Jun; 77(6):421-30. PubMed ID: 17921048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective.
    Tremlett HL; Oger J
    Mult Scler; 2008 Jan; 14(1):94-105. PubMed ID: 17881392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors that influence spontaneous reporting of adverse drug reactions: a model centralized in the medical professional.
    Herdeiro MT; Polonia J; Gestal-Otero JJ; Figueiras A
    J Eval Clin Pract; 2004 Nov; 10(4):483-9. PubMed ID: 15482410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reporting of adverse drug reactions: predictors of under-reporting in Malaysia.
    Aziz Z; Siang TC; Badarudin NS
    Pharmacoepidemiol Drug Saf; 2007 Feb; 16(2):223-8. PubMed ID: 16947117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacologic surveillance and safety evaluation of new drugs].
    Reys LL
    Acta Med Port; 1991; 4(3):141-6. PubMed ID: 1950664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of spontaneous adverse drug reaction (ADR) reports using supplementary information.
    Ghosh P; Dewanji A
    Stat Med; 2011 Jul; 30(16):2040-55. PubMed ID: 21544847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers.
    Shin YS; Lee YW; Choi YH; Park B; Jee YK; Choi SK; Kim EG; Park JW; Hong CS
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):910-5. PubMed ID: 19621345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Features of the French postmarketing drug surveillance system. Application to cutaneous effects of nonsteroidal antiinflammatory drugs.
    Albengres E
    J Rheumatol Suppl; 1988 Oct; 17():20-3. PubMed ID: 3204616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a hospital-based adverse drug reaction reporting program.
    Cantú TG; Tyler LS
    Hosp Formul; 1988 Aug; 23(8):658-61. PubMed ID: 10288394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.